同大類學(xué)科其它級(jí)別期刊:
中科院 1區(qū) 期刊 JCR Q1 期刊 中科院 2區(qū) 期刊 JCR Q2 期刊 中科院 3區(qū) 期刊 JCR Q3 期刊 中科院 4區(qū) 期刊 JCR Q4 期刊國(guó)際簡(jiǎn)稱:World J Trad Chinese 參考譯名:世界中醫(yī)藥雜志
主要研究方向:Medicine-Complementary and Alternative Medicine 非預(yù)警期刊 審稿周期: 24 Weeks
《世界中醫(yī)藥雜志》(World Journal Of Traditional Chinese Medicine)是一本由Wolters Kluwer Health出版的以Medicine-Complementary and Alternative Medicine為研究特色的國(guó)際期刊,發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評(píng)論文章和綜述文章,及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn),旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本開放期刊,近三年沒有被列入預(yù)警名單。
The World Journal Of Traditional Chinese Medicine is committed to reporting the research progress of the clinical efficacy and mechanism of action of traditional Chinese medicine, Chinese medicinal materials, acupuncture and moxibustion and moxibustion to doctors and biomedical researchers around the world, so as to provide new ideas and solutions to complex and intractable diseases. Modern research on traditional Chinese medicine includes theories of processing, compatibility of drug properties, safety of traditional Chinese medicine, pharmacology of traditional Chinese medicine and compound medicine, as well as the material basis and mechanism of drug effects; The research on the basic theory of traditional Chinese medicine includes the scientific connotation and biological basis of the basic theory of traditional Chinese medicine; Clinical research in traditional Chinese medicine includes diseases and syndromes, TCM safety, efficacy evaluation, evidence-based and systematic evaluation; Acupuncture and moxibustion includes acupuncture and moxibustion, uterine specificity, acupoints and drug compatibility, and the effect mechanism of acupuncture and moxibustion efficacy evaluation.
CiteScore | SJR | SNIP | CiteScore 指數(shù) | ||||||||
5.4 | 0.567 | 1.369 |
|
名詞解釋:CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù),是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年(含計(jì)算年度)的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如,2022年的 CiteScore 計(jì)算方法為:2022年的 CiteScore =2019-2022年收到的對(duì)2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量 注:文獻(xiàn)類型包括:文章、評(píng)論、會(huì)議論文、書籍章節(jié)和數(shù)據(jù)論文。
Top期刊 | 綜述期刊 | 大類學(xué)科 | 小類學(xué)科 | ||
否 | 否 | 醫(yī)學(xué) | 3區(qū) | INTEGRATIVE & COMPLEMENTARY MEDICINE 全科醫(yī)學(xué)與補(bǔ)充醫(yī)學(xué) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué):研究與實(shí)驗(yàn) PHARMACOLOGY & PHARMACY 藥學(xué) | 3區(qū) 3區(qū) 3區(qū) |
Top期刊 | 綜述期刊 | 大類學(xué)科 | 小類學(xué)科 | ||
否 | 否 | 醫(yī)學(xué) | 4區(qū) | INTEGRATIVE & COMPLEMENTARY MEDICINE 全科醫(yī)學(xué)與補(bǔ)充醫(yī)學(xué) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué):研究與實(shí)驗(yàn) PHARMACOLOGY & PHARMACY 藥學(xué) | 4區(qū) 4區(qū) 4區(qū) |
按JIF指標(biāo)學(xué)科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
學(xué)科:INTEGRATIVE & COMPLEMENTARY MEDICINE | ESCI | Q1 | 6 / 43 |
87.2% |
學(xué)科:MEDICINE, RESEARCH & EXPERIMENTAL | ESCI | Q2 | 58 / 189 |
69.6% |
學(xué)科:PHARMACOLOGY & PHARMACY | ESCI | Q1 | 69 / 354 |
80.6% |
按JCI指標(biāo)學(xué)科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
學(xué)科:INTEGRATIVE & COMPLEMENTARY MEDICINE | ESCI | Q2 | 15 / 43 |
66.28% |
學(xué)科:MEDICINE, RESEARCH & EXPERIMENTAL | ESCI | Q2 | 79 / 189 |
58.47% |
學(xué)科:PHARMACOLOGY & PHARMACY | ESCI | Q2 | 144 / 354 |
59.46% |
Frontiers In Public Health
中科院 3區(qū) JCR Q2
Frontiers In Pharmacology
中科院 2區(qū) JCR Q1
Biomedicine & Pharmacotherapy
中科院 2區(qū) JCR Q1
Discover Oncology
中科院 4區(qū) JCR Q2
Bmc Psychiatry
中科院 2區(qū) JCR Q2
Bmc Neurology
中科院 3區(qū) JCR Q3
Journal Of Materials Chemistry B
中科院 3區(qū) JCR Q1
Medcomm
中科院 3區(qū) JCR Q1